Abstract |
Activating mutations in the NOTCH1 pathway are frequent in pediatric T-cell acute lymphoblastic leukemia ( T-ALL) but their role in refining risk stratification is unclear. We screened 162 pediatric T-ALL patients treated on the MRC UKALL2003 trial for NOTCH1/FBXW7 gene mutations and related genotype to response to therapy and long-term outcome. Overall, 35% were wild-type (WT) for both genes (NOTCH1(WT)FBXW7(WT)), 38% single NOTCH1 mutant (NOTCH1(Single)FBXW7(WT)), 3% just FBXW7 mutant (NOTCH1(WT)FBXW7(MUT)) and 24% either double NOTCH1 mutant (NOTCH1(Double)FBXW7(WT)) or mutant in both genes (NOTCH1(MUT)FBXW7(MUT)), hereafter called as NOTCH1±FBXW7(Double). There was no difference between groups in early response to therapy, but NOTCH1±FBXW7(Double) patients were more likely to be associated with negative minimal residual disease (MRD) post-induction than NOTCH1(WT)FBXW7(WT) patients (71% versus 40%, P=0.004). Outcome improved according to the number of mutations, overall survival at 5 years 82%, 88% and 100% for NOTCH1(WT)FBXW7(WT), NOTCH1(Single)FBXW7(WT) and NOTCH1±FBXW7(Double) patients, respectively (log-rank P for trend=0.005). Although 14 NOTCH1±FBXW7(Double) patients were classified as high risk (slow response and/or MRD positive), only two had disease progression and all remain alive. Patients with double NOTCH1 and/or FBXW7 mutations have a very good outcome and should not be considered for more intensive therapy in first remission, even if slow early responders or MRD positive after induction therapy.
|
Authors | S Jenkinson, K Koo, M R Mansour, N Goulden, A Vora, C Mitchell, R Wade, S Richards, J Hancock, A V Moorman, D C Linch, R E Gale |
Journal | Leukemia
(Leukemia)
Vol. 27
Issue 1
Pg. 41-7
(Jan 2013)
ISSN: 1476-5551 [Electronic] England |
PMID | 22814294
(Publication Type: Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Cell Cycle Proteins
- DNA, Neoplasm
- F-Box Proteins
- F-Box-WD Repeat-Containing Protein 7
- FBXW7 protein, human
- Receptor, Notch1
- Vincristine
- Dexamethasone
- Ubiquitin-Protein Ligases
- Asparaginase
- Daunorubicin
|
Topics |
- Adolescent
- Adult
- Antineoplastic Combined Chemotherapy Protocols
(therapeutic use)
- Asparaginase
(administration & dosage)
- Cell Cycle Proteins
(genetics)
- Child
- Child, Preschool
- Cohort Studies
- DNA, Neoplasm
(genetics)
- Daunorubicin
(administration & dosage)
- Dexamethasone
(administration & dosage)
- F-Box Proteins
(genetics)
- F-Box-WD Repeat-Containing Protein 7
- Female
- Genotype
- Humans
- Infant
- Male
- Mutation
(genetics)
- Polymerase Chain Reaction
- Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
(drug therapy, genetics, mortality)
- Prognosis
- Receptor, Notch1
(genetics)
- Remission Induction
- Survival Rate
- Ubiquitin-Protein Ligases
(genetics)
- Vincristine
(administration & dosage)
- Young Adult
|